0001493152-24-006314.txt : 20240214 0001493152-24-006314.hdr.sgml : 20240214 20240214073522 ACCESSION NUMBER: 0001493152-24-006314 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240214 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sonnet BioTherapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001106838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 522102141 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35570 FILM NUMBER: 24632317 BUSINESS ADDRESS: STREET 1: 100 OVERLOOK CENTER STREET 2: SUITE 102 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-375-2227 MAIL ADDRESS: STREET 1: 100 OVERLOOK CENTER STREET 2: SUITE 102 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: Chanticleer Holdings, Inc. DATE OF NAME CHANGE: 20050510 FORMER COMPANY: FORMER CONFORMED NAME: TULVINE SYSTEMS INC DATE OF NAME CHANGE: 20000214 8-K 1 form8-k.htm
false 0001106838 0001106838 2024-02-14 2024-02-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 14, 2024

 

SONNET BIOTHERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-35570   20-2932652
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

100 Overlook Center, Suite 102
Princeton, New Jersey		   08540
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (609) 375-2227

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 Par Value   SONN   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On February 14, 2024, Sonnet BioTherapeutics Holdings, Inc. (the “Registrant”) issued a press release regarding its financial results for the three months ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

Forward-Looking Statements

 

This report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,” “plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks and uncertainties that exist in the Registrant’s operations and business environment, which may be beyond the Registrant’s control, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. For example, forward-looking statements include, without limitation: statements regarding prospects for additional customers; market forecasts; projections of earnings, revenues, synergies, accretion or other financial information; and plans, strategies and objectives of management for future operations. The risks and uncertainties referred to above include, but are not limited to, risks detailed from time to time in the Registrant’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended September 30, 2023. These risks could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Registrant. Forward-looking statements represent the judgment of management of the Registrant regarding future events. Although the Registrant believes that the expectations reflected in such forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance that such expectations will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Exhibit
     
99.1   Press Release, dated February 14, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Sonnet BioTherapeutics Holdings, Inc.
  a Delaware corporation
  (Registrant)
   
Date: February 14, 2024 By: /s/ Pankaj Mohan, Ph.D.
  Name: Pankaj Mohan, Ph.D.
  Title: Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

 

●Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offering
●Extensive preclinical data on SON-1210 published in Frontiers in Immunology
●Received approval and executed agreement to sell New Jersey state net operating losses (NOLs) for expected net proceeds of $4.3 million
●Enrollment of the Phase 1b portion of the SON-080 trial in chemotherapy-induced peripheral neuropathy (CIPN) has completed

 

PRINCETON, NJ / ACCESSWIRE / February 14, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapeutic drugs for cancer, announced today its financial results for the three months ended December 31, 2023 and provided a business update.

 

“This last quarter set the stage for an exciting year across Sonnet’s pipeline, highlighted by the progress of the combination study of SON-1010 and atezolizumab in platinum-resistant ovarian cancer (PROC), where we continue to expect safety data during the first half of 2024.” commented Pankaj Mohan, Ph.D., Founder and CEO. “Additionally, enrollment of the Phase 1b portion of the SON-080 study in patients with CIPN is now finished. We believe this trial will yield important safety data that could help position the asset for a potential partnering opportunity in this indication, as well as in diabetic peripheral neuropathy (DPN), both indications of high unmet medical need. On the operations side, we continue the work to optimize our cash usage and runway, including leveraging tax credits. From the sale of the New Jersey NOLs, we expect to receive net proceeds of $4.3 million, after deducting expected fees, during February 2024. Pending the completion of this sale, we believe it will extend the funding of our projected operations into the third calendar quarter of 2024. Taken together, we are pleased with the progress of our clinical programs and look forward to updating the market on our continued progress over the balance of 2024.”

 

Fiscal Year 2024 First Quarter and Recent Corporate Updates

 

Sonnet provided the following corporate updates:

 

●On October 17, 2023, announced that interim data from the SB101 clinical trial of the company’s proprietary Fully Human Albumin Binding (FHAB) candidate, SON-1010 (IL12- FHAB), would be presented by Dr. Sant Chawla, a key opinion leader in the field of sarcoma research, at the Connective Tissue Oncology Society Annual Meeting 2023, held November 1-4, 2023, in Dublin, Ireland.
●On October 25, 2023, announced the pricing of an underwritten public offering of 2,843,750 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 5,687,500 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with two investor warrants at a combined offering price of $1.60, for total gross proceeds of approximately $4.55 million (final net proceeds were $3.9 million), before underwriting discounts and commissions and offering expenses payable by Sonnet.

 

 

 

 

●On December 21, 2023, announced the publication of extensive preclinical data on SON-1210 in Frontiers in Immunology. SON-1210, Sonnet’s lead proprietary bifunctional compound, combines the company’s FHAB construct with a novel single-chain Interleukin 12 (IL-12) and fully human Interleukin 15 (IL-15). The paper, entitled “SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy”, demonstrated the robust binding affinity of SON-1210 to albumin and the anticipated in vitro activity and tumor model efficacy that might be expected from the body of research on native IL-12 and IL-15. In the B16F10 melanoma model, a single dose resulted in a marked reduction of tumor growth that was concomitant with increased IFNγ and augmented immune cell numbers and activity in the tumor microenvironment. Repeat doses in non-human primates displayed excellent safety and tolerability and were similarly accompanied by increased IFNγ levels.
●In December 2023, Sonnet received preliminary approval of its application to sell up to $4.8 million of its New Jersey state net operating losses (NOLs) through the Technology Business Tax Certificate Transfer Program. On January 24, 2024, the Company executed an agreement pursuant to the program whereby a buyer has agreed to purchase, and the Company agreed to sell, such NOLs. Sonnet expects to receive net proceeds of $4.3 million, after deducting expected fees, during February 2024. Pending the completion of the sale of the New Jersey NOLs, Sonnet believes it will extend the funding of its projected operations into the third calendar quarter of 2024.
●Also during December 2023, Sonnet received a $0.8 million net cash refund from the research and development tax incentive program in Australia.
●Safety was recently reviewed for the 2nd dose-escalation cohort in the SB221 Phase 1b combination study (NCT05756907) in patients with platinum-resistant ovarian cancer (PROC) and enrollment has begun in the 3rd cohort. Enrollment continues in the final dose-escalation cohort with SON-1010 monotherapy in SB101 (NCT05352750) cancer patients. Safety updates for both studies are expected during the first half of 2024.
●Enrollment has finished in the Phase 1b safety portion of the SB211 study of SON-080 (NCT05435742) in patients with persistent CIPN. A safety update from this trial is expected during the first quarter of 2024.
●Regarding the agreement with Janssen, the parties have completed two combination studies in a prostate tumor model. A review of the resulting data remains ongoing.

 

“As our pipeline continues to advance, we remain focused on areas for further operating expense reductions.” said Jay Cross, CFO. “Furthermore, we are diligently working to expand on our business development accomplishments, in an otherwise highly competitive environment.”

 

 

 

 

FY 2024 First Quarter Ended December 31, 2023, Financial Results

 

●As of December 31, 2023, Sonnet had $3.0 million cash on hand and no debt.
●Research and development expenses were $0.6 million for the three months ended December 31, 2023, compared to $3.7 million for the three months ended December 31, 2022. The decrease of $3.1 million was primarily due to the cancellation of accrued but unpaid bonuses that had been awarded for fiscal years 2022 and 2023 in the amount of $1.0 million, as well as due to cost saving initiatives, as we are managing expenses for liquidity purposes and are tightening our focus on the research and development projects we have assessed to have the greatest near-term potential. In addition to transitioning product development activities to cost advantaged locations such as India and Australia, we have reduced expenditures on tertiary programs and suspended antiviral development related to SON-1010.
●General and administrative expenses were $0.7 million for the three months ended December 31, 2023, compared to $1.9 million for the three months ended December 31, 2022. The decrease of $1.3 million relates primarily to the cancellation of accrued but unpaid bonuses that had been awarded for fiscal years 2022 and 2023 in the amount of $0.9 million, and due to cost saving initiatives, as we are managing expenses for liquidity purposes.

 

About Sonnet BioTherapeutics Holdings, Inc.

 

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. Sonnet’s FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.

 

Forward-Looking Statements

 

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s cash runway, the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Sonnet BioTherapeutics Investor Contact:

 

Jack Yauch

Solebury Strategic Communications

862-754-1024

jyauch@soleburystrat.com

 

SOURCE: Sonnet BioTherapeutics, Inc.

 

 

 

 

Sonnet BioTherapeutics Holdings, Inc.

Consolidated Balance Sheets

(unaudited)

 

   December 31, 2023   September 30, 2023 
Assets          
Current assets:          
Cash  $3,021,392   $2,274,259 
Prepaid expenses and other current assets   1,408,280    1,677,396 
Incentive tax receivable   194,111    786,574 
Total current assets   4,623,783    4,738,229 
Property and equipment, net   30,155    33,366 
Operating lease right-of-use asset   176,926    193,689 
Deferred offering costs   15,000    49,988 
Other assets   491,862    414,206 
Total assets  $5,337,726   $5,429,478 
Liabilities and stockholders’ equity (deficit)          
Current liabilities:          
Accounts payable  $1,655,390   $2,201,999 
Accrued expenses and other current liabilities   923,191    3,230,922 
Current portion of operating lease liability   75,730    73,048 
Deferred income   —    18,626 
Total current liabilities   2,654,311    5,524,595 
Operating lease liability, net of current portion   110,956    130,863 
Total liabilities   2,765,267    5,655,458 
Commitments and contingencies (Note 4)          
Stockholders’ equity (deficit):          
Common stock, $0.0001 par value: 125,000,000 shares authorized; 3,069,516 and 1,750,426 issued and outstanding at December 31, 2023 and September 30, 2023, respectively   307    175 
Additional paid-in capital   113,984,414    110,017,598 
Accumulated deficit   (111,412,262)   (110,243,753)
Total stockholders’ equity (deficit)   2,572,459    (225,980)
Total liabilities and stockholders’ equity (deficit)  $5,337,726   $5,429,478 

 

 

 

 

Sonnet BioTherapeutics Holdings, Inc.
Consolidated Statements of Operations
(unaudited)

   Three Months Ended December 31, 
   2023   2022 
Collaboration revenue  $18,626   $37,255 
Operating expenses:          
Research and development   644,042    3,745,940 
General and administrative   653,455    1,903,709 
Total operating expenses   1,297,497    5,649,649 
Loss from operations   (1,278,871)   (5,612,394)
Foreign exchange gain   110,362    70,252 
Net loss  $(1,168,509)  $(5,542,142)
           
Per share information:          
Net loss per share, basic and diluted  $(0.31)  $(17.62)
Weighted average shares outstanding, basic and diluted   3,797,753    314,472 

 

 

 

 EX-101.SCH 3 sonn-20240214.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sonn-20240214_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 sonn-20240214_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 14, 2024
Entity File Number 001-35570
Entity Registrant Name SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Entity Central Index Key 0001106838
Entity Tax Identification Number 20-2932652
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Overlook Center
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code (609)
Local Phone Number 375-2227
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 Par Value
Trading Symbol SONN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sonnetbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm sonn-20240214.xsd sonn-20240214_lab.xml sonn-20240214_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "SONN", "nsuri": "http://sonnetbio.com/20240214", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "sonn-20240214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sonn-20240214_lab.xml" ] }, "presentationLink": { "local": [ "sonn-20240214_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://sonnetbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-006314-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-006314-xbrl.zip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end XML 16 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001106838 2024-02-14 2024-02-14 iso4217:USD shares iso4217:USD shares false 0001106838 8-K 2024-02-14 SONNET BIOTHERAPEUTICS HOLDINGS, INC. DE 001-35570 20-2932652 100 Overlook Center Suite 102 Princeton NJ 08540 (609) 375-2227 false false false false Common Stock, $0.0001 Par Value SONN NASDAQ false